Greenwich LifeSciences (NASDAQ:GLSI) CEO Snehal Patel Purchases 4,100 Shares

Greenwich LifeSciences, Inc. (NASDAQ:GLSI) CEO Snehal Patel purchased 4,100 shares of the stock in a transaction that occurred on Thursday, December 18th. The shares were purchased at an average price of $12.62 per share, for a total transaction of $51,742.00. Following the completion of the purchase, the chief executive officer directly owned 5,592,202 shares of the company’s stock, valued at approximately $70,573,589.24. This trade represents a 0.07% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link.

Snehal Patel also recently made the following trade(s):

• On Tuesday, November 25th, Snehal Patel acquired 4,600 shares of Greenwich LifeSciences stock. The shares were purchased at an average cost of $8.37 per share, for a total transaction of $38,502.00.
• On Friday, November 7th, Snehal Patel acquired 10,600 shares of Greenwich LifeSciences stock. The shares were purchased at an average price of $8.43 per share, for a total transaction of $89,358.00.
• On Friday, October 31st, Snehal Patel bought 2,300 shares of Greenwich LifeSciences stock. The stock was purchased at an average cost of $9.26 per share, with a total value of $21,298.00.

Greenwich LifeSciences Price Performance

Shares of Greenwich LifeSciences stock opened at $13.01 on Friday. Greenwich LifeSciences, Inc. has a 52-week low of $7.78 and a 52-week high of $14.47. The firm has a market capitalization of $180.19 million, a PE ratio of -8.91 and a beta of 1.61. The company’s fifty day moving average price is $9.22 and its two-hundred day moving average price is $10.25.

Greenwich LifeSciences (NASDAQ:GLSI) last issued its earnings results on Friday, November 14th. The company reported ($0.30) earnings per share for the quarter, meeting the consensus estimate of ($0.30). Analysts predict that Greenwich LifeSciences, Inc. will post -0.8 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Greenwich LifeSciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Bank of America Corp DE increased its holdings in shares of Greenwich LifeSciences by 22.3% during the fourth quarter. Bank of America Corp DE now owns 7,262 shares of the company’s stock worth $82,000 after buying an additional 1,322 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in shares of Greenwich LifeSciences by 15.5% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 19,007 shares of the company’s stock worth $181,000 after acquiring an additional 2,552 shares in the last quarter. HighTower Advisors LLC bought a new stake in Greenwich LifeSciences during the 1st quarter worth approximately $147,000. Strs Ohio acquired a new stake in Greenwich LifeSciences during the 1st quarter valued at $177,000. Finally, Rhumbline Advisers raised its position in Greenwich LifeSciences by 48.7% in the 1st quarter. Rhumbline Advisers now owns 9,673 shares of the company’s stock valued at $92,000 after purchasing an additional 3,168 shares during the last quarter. 4.16% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Greenwich LifeSciences in a report on Tuesday, October 14th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $42.00.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc (NASDAQ: GLSI) is a clinical-stage biotechnology company focused on the development of novel immune modulators for the treatment of cancer and autoimmune diseases. The company’s product pipeline includes candidates engineered to activate or regulate key components of the innate and adaptive immune systems, with programs advancing through preclinical and early-stage clinical studies.

Headquartered in Greenwich, Connecticut, Greenwich LifeSciences conducts its research and development activities primarily in the United States.